Sugi Predict

Sugi Predict / Compounds / SCHEMBL21070656

SCHEMBL21070656

SCHEMBL21070656

NCCCOCCCOCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O

nearest known ligand 0.67

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ CRBN Q96SW2 11/20 0.67
▸ CA2 P00918 2/20 0.67
▸ DDB1 Q16531 9/20 0.64
▸ HDAC1 Q13547 4/20 0.59
▸ HDAC2 Q92769 4/20 0.59
▸ HDAC3 O15379 3/20 0.59
▸ NCOR2 Q9Y618 3/20 0.59
▸ STAT3 P40763 5/20 0.58
▸ TNF P01375 1/20 0.57
▸ IL1B P01584 1/20 0.57
▸ TBXA2R P21731 1/20 0.57
▸ IKZF1 Q13422 1/20 0.57
▸ IKZF3 Q9UKT9 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21070288 0.99 CRBN (0.68) CRBNCA2DDB1HDAC1HDAC2
SCHEMBL19436953 0.98 CRBN (0.69) CRBNCA2DDB1HDAC1HDAC2
Hydrochloric Acid SCHEMBL21070400 0.98 CRBN (0.67) CRBNCA2DDB1HDAC1HDAC2
SCHEMBL19451339 0.98 CRBN (0.69) CRBNCA2DDB1HDAC1HDAC2
Hydrochloric Acid SCHEMBL28457963 0.97 CRBN (0.69) CRBNCA2DDB1HDAC1HDAC2
Hydrochloric Acid SCHEMBL22442980 0.97 CRBN (0.69) CRBNCA2DDB1HDAC1HDAC2
SCHEMBL26815233 0.95 CRBN (0.68) CRBNCA2DDB1HDAC1HDAC2
SCHEMBL23302448 0.95 CRBN (0.65) CRBNCA2DDB1HDAC1HDAC2
SCHEMBL23884205 0.94 CRBN (0.67) CRBNCA2DDB1HDAC1HDAC2
SCHEMBL23884292 0.94 CRBN (0.69) CRBNCA2DDB1HDAC1HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479840-B2 HMG-CoA reductase degradation inducing compound UPPTHERA INC. (KR) 2025-11-25 — — US disclosed
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-10-23 — — US disclosed
EP-4613773-A2 IRAK DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
EP-3731869-B1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2025-07-23 — — EP disclosed
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-01-02 — — US disclosed
US-12168057-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2024-12-17 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-11723980-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2023-08-15 — — US disclosed
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-04-06 — — US disclosed
US-20230078961-A1 HMG-CoA Reductase Degradation Inducing Compound UPPTHERA INC. (KR) 2023-03-16 — — US disclosed
US-20220356185-A1 MERTK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2022-11-10 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
US-11318205-B1 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2022-05-03 — — US disclosed
WO-2021201577-A1 HMG-COA REDUCTASE DEGRADATION INDUCING COMPOUND UPPTHERA (KR) 2021-10-07 — — WO disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
US-10874743-B2 IRAK degraders and uses thereof KYMERA THERAPEUTICS, INC. (US) 2020-12-29 — — US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2019-06-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10874743-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CRBN 187/4885CA2 4617/4885DDB1 1267/4885
US-20230106066-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885CA2 4617/4885DDB1 1267/4885
US-20250325673-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885CA2 4617/4885DDB1 1267/4885
US-20250000985-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885CA2 4617/4885DDB1 1267/4885
US-11723980-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CRBN 187/4885CA2 4617/4885DDB1 1267/4885
US-12168057-B2 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CRBN 187/4885CA2 4617/4885DDB1 1267/4885
US-20220356185-A1 MERTK DEGRADERS AND USES THEREOF MERTK, ITK, CRKL CRBN 183/4885CA2 4280/4885DDB1 3837/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885CA2 4617/4885DDB1 1267/4885
US-20190192668-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 CRBN 187/4885CA2 4617/4885DDB1 1267/4885
US-20230078961-A1 HMG-CoA Reductase Degradation Inducing Compound HMGCR, HMGB2, LDLR CRBN 1616/4885CA2 4536/4885DDB1 798/4885
US-12479840-B2 HMG-CoA reductase degradation inducing compound HMGCR, HMGB2, LDLR CRBN 1616/4885CA2 4536/4885DDB1 798/4885
US-11318205-B1 IRAK degraders and uses thereof IRAK2, IRAK3, IRAK1 CRBN 187/4885CA2 4617/4885DDB1 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.